Michael R. Setzer

Michael R. Setzer

Auto-generated profile, based on publicly available information

Michael R. Setzer

Uniformed Services University of the Health Sciences

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
PDF file
MSMichael R. Setzer
Michael R. Setzer
DRDebra L. Roter
Debra L. Roter

10 July 2024 in Journal of Genetic Counseling
Verified
Journal Article
Open access
RMRachel Gore Moses
Rachel Gore Moses
CJColleen Olivia Jodarski
Colleen Olivia Jodarski
MSMichael Setzer
Michael Setzer
KLKatie L. Lewis
Katie L. Lewis
JYJia Yan
Jia Yan
MSMorgan Similuk
Morgan Similuk
Psychiatric genetic counseling (GC) has been associated with patient‐reported increases in empowerment (perceived control, emotional regulation, and hope). We sought to evaluate the extent to which patients' psychological state at the time of GC is related to changes in empowerment. Participants with a history of major depressive disorder and/or bipolar disorder that had been refractory to treatment underwent psychiatric GC remotely from 2022 to 2023. GC was performed by four genetic counselors and included discussion of perceived causes of illness, multifactorial inheritance, and protective factors. Empowerment, depression, and anxiety were measured immediately prior to GC via online survey by the GCOS‐16, PHQ‐9, and GAD‐7, respectively. Empowerment was re‐assessed 2 weeks later. In total, 66/161 (41.0%) invited individuals completed both the baseline and follow‐up surveys. Participants completing both surveys were 54.6% female, 84.8% white, and ranged in age from 22 to 78 years (mean = 54.8 years). Overall, a significant change in mean empowerment was not observed (p = 0.38); however, there were moderating effects by baseline psychological state. A multiple linear regression model incorporating PHQ‐9, GAD‐7 and baseline GCOS‐16 score predicted change in empowerment with a large effect (F = 5.49, R2 = 0.21, p < 0.01). A higher score on the PHQ‐9 was associated with decreases in empowerment from pre to post GC. Higher scores on the GAD‐7 and lower baseline GCOS‐16 scores were associated with increases in empowerment. Further, two‐way ANOVA was conducted to assess change in empowerment between subgroups based on the level of anxiety and depression. Those with low depression and high anxiety reported significant increases in empowerment (F = 6.64, p = 0.01). These findings suggest that psychiatric GC may be especially helpful to individuals experiencing anxiety and low baseline empowerment. Alternative approaches may be needed to best meet the needs of those experiencing significant depression.

23 May 2023 in Clinical Immunology
Verified
Journal Article
Closed access
BBBreanna Beers
Breanna Beers
HDHannah Davidson
Hannah Davidson
KLKatie Lewis
Katie Lewis
MSMichael Setzer
Michael Setzer
MWMagdalena Walkiewicz
Magdalena Walkiewicz
MSMorgan Similuk
Morgan Similuk

13 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EWEmma L. Winterlind
Emma L. Winterlind
SMSamantha G. Malone
Samantha G. Malone
MSMichael R. Setzer
Michael R. Setzer
MMMikela A. Murphy
Mikela A. Murphy
DSDavid Saunders
David Saunders
JGJoshua C. Gray
Joshua C. Gray
N-acetylcysteine (NAC) may serve as a novel pharmacotherapy for substance use and substance craving in individuals with substance use disorders (SUDs), possibly through its potential to regulate glutamate. Though prior meta-analyses generally support NAC’s efficacy in reducing symptoms of craving, individual trials have found mixed results. The aims of the this updated meta-analysis were to (1) examine the efficacy of NAC in treating symptoms of craving in individuals with a SUD and (2) explore subgroup differences, risk of bias, and publication bias across trials. Database searches of PubMed, Cochrane Library, and ClinicalTrials.gov were conducted in June and July of 2023 to identify relevant randomized control trials (RCTs). The meta-analysis consisted of 9 trials which analyzed data from a total of 623 participants. The most targeted substance in the clinical trials was alcohol (3/9; 33.3%), followed by tobacco (2/9; 22.2%) and multiple substances (2/9; 22.2%). Meta-analysis, subgroup analyses, and leave-one-out analyses were conducted to examine treatment effect on craving symptoms and adverse events (AEs). Risk of bias assessments, Egger’s tests, and funnel plot tests were conducted to examine risk of bias and publication bias. NAC did not significantly outperform placebo in reducing symptoms of craving in the meta-analysis (SMD = 0.189, 95% CI = -0.015 - 0.393). Heterogeneity was very high in the meta-analysis (99.26%), indicating that findings may have been influenced by clinical or methodological differences in the study protocols. Additionally, results indicate that there may be publication bias present. Overall, our findings are contrary to those of prior meta-analyses, suggesting limited impact of NAC on substance craving. However, the high heterogeneity and presence of publication bias identified warrants cautious interpretation of the meta-analytic outcomes.

5 July 2026 in Psychological Reports
Verified
Journal Article
Closed access
MSMichael R. Setzer
Michael R. Setzer
SMSamantha G. Malone
Samantha G. Malone
RIRavi A. Iyer
Ravi A. Iyer
EWEmma L. Winterlind
Emma L. Winterlind
JGJoshua C. Gray
Joshua C. Gray
Flourishing and quality of life are related constructs often used to measure overall well-being, but it is unclear whether they capture the same underlying facets of well-being or provide complementary information. This study evaluated the relationship between a multidimensional flourishing measure (i.e., the Harvard Human Flourishing Program Measure; FM) and a commonly used quality of life instrument (i.e., the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, Q-LES-SF). Analysis was performed on a sample of 302 adult participants recruited using the online survey platform Prolific. Participants completed the FM and Q-LES-SF, as well as the Patient Health Questionnaire-9 (PHQ-9; depression), Generalized Anxiety Disorder-7 (GAD-7), Alcohol Use Disorders Identification Test (AUDIT), and the PROMIS Smoking/Nicotine Dependence scale. Pearson correlations were used to assess associations between variables, Fisher’s z -tests compared correlation magnitudes, and linear regressions tested incremental validity. FM and Q-LES-SF scores were strongly positively correlated ( r = 0.81, p < .001). Both FM and Q-LES-SF showed significant negative correlations with PHQ-9 ( r s = −0.69, −0.74), GAD-7 ( r s = −0.65, −0.66), and AUDIT ( r s = −0.17, −0.18, respectively) scores ( p s < .001), with no significant differences between correlation magnitudes. Adding FM as a predictor alongside QL significantly improved the prediction of PHQ-9 and GAD-7 scores but not AUDIT or cigarette dependence scores. These findings are a first step in understanding the convergent and incremental validity of FM and QL and if the separate research programs for each measure may be mutually informative.

18 September 2026 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
MSMichael Setzer
Michael Setzer
RKRachel Kember
Rachel Kember
EHEmily Hartwell
Emily Hartwell
ZPZachary Piserchia
Zachary Piserchia
JGJoel Gelernter
Joel Gelernter
JGJoshua Gray
Joshua Gray
Background: Attention-deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs) commonly co-occur and have overlapping genetic liabilities. Less is known regarding the phenomenology and genetics of ADHD in a cohort enriched for SUDs and the extent to which ADHD genetic liability contributes to SUD risk when controlling for substance specific genetic risk. Methods: We used data from the Yale-Penn cohort, which comprises ~14,000 individuals ascertained for SUDs and/or as controls. Psychiatric and substance use phenotypes were ascertained from the semi-structured assessment for drug dependence and alcohol survey for all participants. Polygenic scores (PGSs) were developed for ADHD and multiple substance-related traits using summary statistics from large genome-wide association studies on participants with genetic data ( N = 10,275). Results: Participants who met DSM-IV Criteria for ADHD had significantly increased odds for every DSM-5 SUD analyzed, greater polysubstance use, and younger age of onset of substance use. Among participants of European-like ancestry, ADHD PGS was associated with multiple SUDs, even after controlling for substance-specific PGS. Of the substance-related PGS, only the smoking initiation PGS was associated with ADHD diagnosis and criterion count and only among individuals of European-like ancestry. Conclusions: In this sample, ADHD was associated with increased risk for SUDs and earlier onset of substance use. Additionally, genetic liability to ADHD was independently associated with multiple SUDs and SUD criteria counts. PGS for substance-related traits tended to be less significantly associated with ADHD. Further studies in large, diverse populations are needed to enhance our understanding of these associations.